199 related articles for article (PubMed ID: 29643323)
1. Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Goto H; Mita T; Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Nishimura H; Kuroda H; Matsubara T; Gosho M; Ishii H; Watada H
Endocr J; 2018 Jun; 65(6):657-668. PubMed ID: 29643323
[TBL] [Abstract][Full Text] [Related]
2. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Kurozumi A; Okada Y; Satoh H; Inoue I; Chimori H; Akita E; Shiraiwa T; Fujitani Y; Mita T; Gosho M; Watada H
Endocr J; 2018 Apr; 65(4):415-425. PubMed ID: 29367471
[TBL] [Abstract][Full Text] [Related]
3. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
[TBL] [Abstract][Full Text] [Related]
4. Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.
Parthan G; Bhansali S; Kurpad AV; Walia R; Bhat K; Bhansali A
BMC Pharmacol Toxicol; 2018 Jul; 19(1):38. PubMed ID: 29970184
[TBL] [Abstract][Full Text] [Related]
5. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin.
Takahara M; Shiraiwa T; Katakami N; Kaneto H; Matsuoka TA; Shimomura I
Endocr J; 2014; 61(5):447-56. PubMed ID: 24561488
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
[TBL] [Abstract][Full Text] [Related]
8. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Ono Y; Kamoshima H; Nakamura A; Nomoto H
Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Iwamoto Y; Tajima N; Kadowaki T; Nonaka K; Taniguchi T; Nishii M; Arjona Ferreira JC; Amatruda JM
Diabetes Obes Metab; 2010 Jul; 12(7):613-22. PubMed ID: 20590736
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
Koyama T; Tanaka A; Yoshida H; Oyama JI; Toyoda S; Sakuma M; Inoue T; Otsuka Y; Node K
Heart Vessels; 2018 Aug; 33(8):958-964. PubMed ID: 29427024
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
13. Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
Kraaijenhof J; Muskiet MHA; Tonneijck L; Ouwens DM; Kramer MHH; van Raalte DH; Smits MM
Diabetes Obes Metab; 2020 Oct; 22(10):1847-1856. PubMed ID: 32476255
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
15. Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
Horie Y; Hayashi N; Dugi K; Takeuchi M
Trials; 2009 Sep; 10():82. PubMed ID: 19732457
[TBL] [Abstract][Full Text] [Related]
16. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Jones RB; Vickers SP; Cheetham SC; Headland KR; Mark M; Klein T
Eur J Pharmacol; 2014 Apr; 729():59-66. PubMed ID: 24530555
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
Wang W; Yang J; Yang G; Gong Y; Patel S; Zhang C; Izumoto T; Ning G
J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
[TBL] [Abstract][Full Text] [Related]
19. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
Tripolt NJ; Aberer F; Riedl R; Url J; Dimsity G; Meinitzer A; Stojakovic T; Aziz F; Hödl R; Brachtl G; Strunk D; Brodmann M; Hafner F; Sourij H
Cardiovasc Diabetol; 2018 May; 17(1):71. PubMed ID: 29773079
[TBL] [Abstract][Full Text] [Related]
20. Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Satoh H; Ohira T; Moriya C; Inoue I; Kuribayashi S; Seino H; Hirai H; Hiyoshi T; Watada H;
Diabetes Metab; 2017 Dec; 43(6):550-553. PubMed ID: 28947255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
